The 4 analysts offering 12-month price forecasts for Matinas BioPharma Holdings Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +254.65% increase from the last price of 0.85.
The current consensus among 4 polled investment analysts is to Buy stock in Matinas BioPharma Holdings Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.03
Reporting Date Nov 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.